RecruitingNCT02135705
LOWER: Lomitapide Observational Worldwide Evaluation Registry
Studying Homozygous familial hypercholesterolemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Amryt Pharma
- Principal Investigator
- Janet BoylanAmryt Pharmaceuticals
- Intervention
- Lomitapide(drug)
- Enrollment
- 300 enrolled
- Eligibility
- All sexes
- Timeline
- 2014 – 2028
Study locations (30)
- Brookwood Baptist Medical Center, Birmingham, Alabama, United States
- Springhill Physician Practices, Mobile, Alabama, United States
- Northern Arizona Healthcare, Cottonwood, Arizona, United States
- One Medical, Gilbert, Arizona, United States
- Scottsdale Family Health, Phoenix, Arizona, United States
- Pima Heart, Tucson, Arizona, United States
- Arkansas Heart Center, Fort Smith, Arkansas, United States
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- University of Colorado Health, Aurora, Colorado, United States
- Alfieri Cardiology, Newark, Delaware, United States
- Preventative Cardiology, Inc., Boca Raton, Florida, United States
- Florida Lipid Institute, Winter Park, Florida, United States
- Piedmont Heart Institute, Atlanta, Georgia, United States
- Atlanta Heart Specialists, Cumming, Georgia, United States
- Northside Hospital, Inc., Cumming, Georgia, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02135705 on ClinicalTrials.govOther trials for Homozygous familial hypercholesterolemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07447648Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)
- RECRUITINGPHASE2NCT07489209A Dose-exploration Study of EDP167 in HoFHEddingpharm (Zhuhai) Co., Ltd.
- RECRUITINGPHASE3NCT07037771A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)Arrowhead Pharmaceuticals
- RECRUITINGNANCT06743659Computerized Decision Support for Identification and Management of Familial HypercholesterolemiaBrigham and Women's Hospital
- ACTIVE NOT RECRUITINGPHASE3NCT06712771A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of VSA003 in Chinese HoFH PatientsVisirna Therapeutics HK Limited
- ACTIVE NOT RECRUITINGNCT06832371Evaluation of the Effect of Lomitapide Treatment on Major Adverse Cardiovascular Events (MACE) in Patients With Homozygous Familial HypercholesterolemiaFondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)
- RECRUITINGEARLY PHASE1NCT06458010Clinical Exploration Trial of YOLT-101 in the Treatment of Familial Hypercholesterolemia (FH)RenJi Hospital
- ACTIVE NOT RECRUITINGNCT06275724Specified Drug-use Survey of Leqvio for s.c. Injection.Novartis Pharmaceuticals
See all trials for Homozygous familial hypercholesterolemia →